Despite a nominal 31.35 current ratio, debt-to-equity of 0.02 ($5.3M debt vs. $310.7M equity), and zero goodwill or PPPE, the $639.3M accumulated deficit exceeds book equity twofold, and the reported $48.5M cash balance covers fewer than three quarters at recent burn rates, while equity has drawn down ~11% from $349.0M at 2025Q4.
Fulcrum Therapeutics, Inc. (FULC) balance sheet — 9-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 |
|---|
| Total Current Assets | 310.8M | 357.48M | 249.92M | 242.2M | 207.52M | 226M | 112.91M | 100.08M | 74.09M | 1.34M |
| Cash & Short-Term Investments | 306.55M | 352.31M | 241.02M | 236.22M | 202.92M | 218.16M | 112.91M | 96.71M | 72.8M | 407K |
| Cash Only | 116.41M | 197.53M | 58.21M | 25.56M | 35.1M | 35.41M | 57.05M | 96.71M | 72.8M | 407K |
| Short-Term Investments | 190.13M | 154.77M | 182.81M | 210.66M | 167.82M | 182.75M | 55.86M | 0 | 0 | 0 |
| Accounts Receivable | 1.31M | 1.07M | 3.34M | 2.25M | 1.08M | 4.11M | 2.71M | 111K | 501K | 39K |
| Days Sales Outstanding | - | - | 15.25 | 292.65 | 62.21 | 78.28 | 111.99 | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | -473K | -2.78M | 2.98M | 559K | 734K |
| Days Inventory Outstanding | - | - | - | - | - | - | - | 528.92 | 151.7 | 374.7 |
| Other Current Assets | 1.09M | 5.17M | 0 | 0 | 0 | 0 | 74K | 284K | 238K | 248K |
| Total Non-Current Assets | 9K | 8.8M | 10.79M | 15.49M | 19.17M | 9M | 16.66M | 10.36M | 11.68M | 3M |
| Property, Plant & Equipment | 0 | 7.07M | 9.58M | 12.39M | 15.97M | 7.37M | 8.4M | 87.94M | 10.55M | 2.94M |
| Fixed Asset Turnover | 0.00x | - | 8.35x | 0.23x | 0.40x | 2.60x | 1.05x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 1.09M | 1.09M | 1.09M | 1.09M | 1.09M | 0 |
| Other Non-Current Assets | 9K | 1.74M | 1.21M | 3.1M | 2.1M | 542K | 7.17M | -78.68M | 38K | 60K |
| Total Assets | 310.81M | 366.28M | 260.72M | 257.69M | 226.69M | 235M | 129.58M | 110.44M | 85.77M | 4.34M |
| Asset Turnover | 0.00x | - | 0.31x | 0.01x | 0.03x | 0.08x | 0.07x | - | - | - |
| Asset Growth % | 169.62% | 40.49% | 1.17% | 13.68% | -3.54% | 81.36% | 17.33% | 28.76% | 1876.29% | - |
| Total Current Liabilities | 8.59M | 13.05M | 11.04M | 13.68M | 16.73M | 19.2M | 26.73M | 12.14M | 4.23M | 2.79M |
| Accounts Payable | 509K | 1.59M | 1.16M | 2.76M | 3.64M | 4.79M | 4.08M | 2.19M | 1.26M | 1.67M |
| Days Payables Outstanding | 1.31K | 418.04 | 6.7 | 14.02 | 17.29 | 25.07 | 25.22 | 388.65 | 342.75 | 854.05 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 2.6M | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 934K | 4.71M | 14.91M | 3.99M | 2.8M | 0 |
| Other Current Liabilities | 0 | 258K | 463K | 396K | 5.34M | 4.71M | 4.79M | 3.68M | 781K | 20K |
| Current Ratio | 36.19x | 27.40x | 22.63x | 17.71x | 12.41x | 11.77x | 4.23x | 8.24x | 17.52x | 0.48x |
| Quick Ratio | 36.19x | 27.40x | 22.63x | 17.71x | 12.41x | 11.80x | 4.33x | 8.00x | 17.39x | 0.22x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 197K | 4.24M | 6.64M | 8.83M | 11.02M | 4.26M | 7.67M | 11.15M | 5.54M | 233K |
| Long-Term Debt | 0 | 4.04M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 34.59M |
| Capital Lease Obligations | 2.76M | 0 | 6.44M | 8.63M | 10.82M | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 197K | 197K | 197K | 197K | 0 | 4.26M | 4.7M | 5.13M | 5.54M | -34.35M |
| Total Liabilities | 8.78M | 17.28M | 17.68M | 22.5M | 27.74M | 23.46M | 34.4M | 23.29M | 9.77M | 3.02M |
| Total Debt | 6.83M | 6.44M | 8.63M | 10.82M | 13.42M | 0 | 17K | 50K | 46K | 34.59M |
| Net Debt | -109.58M | -191.09M | -49.58M | -14.74M | -21.68M | -35.41M | -57.03M | -96.66M | -72.75M | 34.18M |
| Debt / Equity | 0.02x | 0.02x | 0.04x | 0.05x | 0.07x | - | 0.00x | 0.00x | 0.00x | 26.16x |
| Debt / EBITDA | -0.09x | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 1.46x | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 302.03M | 349M | 243.03M | 235.19M | 198.94M | 211.54M | 95.18M | 87.15M | 76M | 1.32M |
| Equity Growth % | 186.66% | 43.6% | 3.33% | 18.22% | -5.95% | 122.25% | 9.21% | 14.67% | 5648.87% | - |
| Book Value per Share | 3.96 | 5.51 | 3.92 | 3.84 | 4.42 | 5.98 | 3.75 | 3.85 | 4.49 | 0.08 |
| Total Shareholders' Equity | 302.03M | 349M | 243.03M | 235.19M | 198.94M | 211.54M | 95.18M | 87.15M | 76M | 1.32M |
| Common Stock | 76K | 67K | 54K | 62K | 52K | 41K | 28K | 23K | 16K | 1K |
| Retained Earnings | -650.29M | -594.28M | -519.4M | -509.67M | -412.34M | -302.47M | -221.62M | -150.8M | -68.12M | -35.54M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -759K | 174K | 130K | -136K | -797K | -397K | -2K | -110.44M | -1.96M | -893K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying FULC stock.
As of 2025, Fulcrum Therapeutics, Inc. (FULC) had total assets of $366.3M including $357.5M in current assets.
Fulcrum Therapeutics, Inc. (FULC) carries total debt of $6.4M, offset by $352.3M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Fulcrum Therapeutics, Inc. (FULC) has total shareholders' equity (book value) of $349.0M ($5.51 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Fulcrum Therapeutics, Inc. (FULC) reported a current ratio of 27.40x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Sub-three-quarter cash runway
Metrics are mathematically derived from official filings.
Equity Reflated by Financing, Now Eroding
Total assets have fallen from $366.3M at 2025Q4 to $324.0M in 2026Q2 while equity declined from $349.0M to $310.7M, a roughly 11 percent drawdown in two quarters, per Fulcrum's quarterly balance sheet disclosures, driven almost entirely by accumulated losses rather than rising obligations.
The $150.6M equity increase between 2025Q3 and 2025Q4 appears consistent with an external capital raise that temporarily rebuilt the base after it had fallen to $198.4M, suggesting funding cadence, not operating performance, drove the most recent strengthening. Since that quarter, equity has given back $38.3M against a $45.0M deepening of accumulated deficit, a gap implying roughly $6.7M of non-loss equity additions, most plausibly stock-based compensation, partially offsetting the drain. Read alongside the prior finding that operating losses near $20M per quarter have not scaled down with R&D cuts, the trajectory suggests the equity cushion will continue to be consumed at a pace set by financing timing.
High Ratio Masks Short Runway
At 2026Q2 Fulcrum reported a 31.35 current ratio and $48.5M of cash against total liabilities of just $13.3M, a nominally fortress-style position, yet at the recent ~$16M quarterly operating cash burn disclosed in its filings the unencumbered cash appears to cover fewer than three quarters.
A current ratio above 31 against total liabilities of only $13.3M suggests minimal near-term obligation pressure, but the metric is flattered by an exceptionally small liability base rather than by abundant current assets, since cash of $48.5M appears to constitute most of the current account. Against quarterly outflows clustered near $16-19M in recent periods, the reported cash balance implies roughly three quarters of runway, so investors should read the ratio as a solvency signal rather than as a liquidity cushion. Cash has nonetheless printed $48.5M only two quarters after the apparent ~$150M equity raise, reinforcing that the cash line should not be evaluated in isolation from the remainder of the asset base.
Debt Runoff Removes Solvency Variable
Fulcrum's total debt has been steadily amortized to $5.3M as of 2026Q2 from $10.1M in 2024Q1, leaving a debt-to-equity ratio of 0.02, based on Fulcrum's reported figures, which suggests leverage servicing is negligible relative to the $310.7M equity base.
Debt has declined monotonically in each of the ten quarters shown, a pattern more consistent with scheduled amortization of a small facility than with covenant-driven repayment, although the data provided does not identify the underlying instrument. With total liabilities of just $13.3M and interest burden immaterial at this scale, refinancing risk appears negligible, which implies cash flow durability at Fulcrum is governed almost entirely by the R&D burn rate rather than by debt service. This removes one solvency variable but concentrates the funding question squarely on future equity issuance.
Asset-Light Base With Opaque Remainder
With goodwill at $0 and property, plant and equipment written down to $0 in 2026Q2 from $6.4M one quarter earlier, Fulcrum's balance sheet carries no acquired intangibles or fixed assets, according to its reported filings, leaving the composition of the remaining ~$275M of assets unexplained by disclosed line items.
The absence of goodwill and the run-off of net PPE from $11.4M in 2024Q1 to zero are consistent with the near-zero capex profile seen in cash flow disclosures, pointing to a fully outsourced, asset-light research model with no manufacturing infrastructure to underwrite. The disappearance of $6.4M of PPE within a single quarter, with no offsetting line visible in the data provided, warrants further investigation as it may reflect disposal, reclassification, or write-off. Because reported cash represents only about 15 percent of the $324.0M asset base, the quality and liquidity of the unitemized remainder appears central to any assessment of balance sheet真实 coverage.
Contributed Capital Fully Backstops Deficit
Fulcrum's accumulated deficit of $639.3M at 2026Q2 exceeds its entire $310.7M book equity by more than twofold, meaning the entire equity cushion traces to contributed capital, in the company's reported equity section, while quarterly losses near $20M continue to erode it.
Because accumulated deficit exceeds book equity by roughly 2x, the equity base is a function of historical share issuance rather than earned capital, leaving no retained-earnings buffer to absorb the current loss run-rate. Equity's $38.3M decline over the first half of 2026 against a $45.0M increase in accumulated deficit implies approximately $6.7M of equity additions from non-loss sources, which appears consistent with the recurring stock-based compensation previously identified and that dilutes holders without adding cash. The $55.4M equity improvement delivered by the 2024Q2 milestone has now been more than fully reversed, suggesting the windfall extended rather than reset the runway.
Unreconciled Cash Migration Clouds Liquidity
Cash fell $147.2M between 2025Q4 and 2026Q1 while total assets dropped only $19.5M and equity $15.7M, implying roughly $128M migrated into non-cash asset categories rather than being spent, per Fulcrum's balance sheets, a reclassification that makes the reported cash runway potentially misleading in either direction.
Total assets fell only $19.5M and equity $15.7M over the same period, so roughly $127.7M appears to have moved into asset categories not itemized in the data provided rather than being consumed by operations, an interpretation that warrants further investigation. If those balances are liquid marketable securities, runway may be materially longer than the $48.5M cash figure implies; if they are illiquid or restricted, headline liquidity could instead be overstated. This single unreconciled movement is the most consequential distortion in Fulcrum's reported balance sheet and should be resolved before sizing any going-concern buffer.